AFP and hepatocellular carcinoma: The same trends were observed in subgroup analysis for OS regarding cabozantinib compared to placebo: (i) faint difference between high ≥ 400 ng/mL (HR 0.71 [0.54–0.94]) vs. low (HR 0.81 [0.62–1.04]) baseline AFP level; (ii) better efficacy when presence of macrovascular invasion and/or extrahepatic disease (HR 0.73 [0.60–0.90]) vs. absence (HR 0.99 [0.59–1.65]); and (iii) better efficacy in HBV-related HCC (HR 0.69 [0.51–0.94]), and by contrast to regorafenib its efficacy in alcohol (HR 0.72 [0.54–0.96]) and inefficacy in HCV (HR 1.11 [0.72–1.71]) [15].